SLC7A11 and osteosarcoma: Guo et al.9 revealed a novel mechanism whereby super-enhancer-driven MLX re-establishes cysteine metabolism in osteosarcoma cells through SLC7A11 to cope with oxidative stress, highlighting the feasibility and clinical prospects of targeting SLC7A11 in osteosarcoma.